Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,104.78 +344.78 (+0.52%) CMC Crypto 200
1,400.04 -17.83 (-1.26%)
DYN Dec 2024 20.000 call
| Previous close | 10.65 |
| Open | N/A |
| Bid | 12.00 |
| Ask | 16.60 |
| Strike | 20.00 |
| Expiry date | 2024-12-20 |
| Day's range | 10.65 - 10.65 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireDyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today highlighted new preclinical data for DYNE-302, its product candidate for facioscapulohumeral muscular dystroph
- GlobeNewswire
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne’s w
- GlobeNewswire
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the closing of its previously announced underwritten public offering of 12,075,000 shares of its common stock at a public offering price of $31.00 per share, which includes 1,575,000 shares issued upon the exercise in full by the underwriters
